Two medicines, side by side
Bisoprolol vs carvedilol
Bisoprolol and carvedilol are both labeled for high blood pressure. Drugs@FDA records approvals of bisoprolol since 1992 and of carvedilol since 1995. Pharmacies paid $0.114 per bisoprolol fumarate 5 mg tablet and $0.0179 per carvedilol 6.25 mg tablet (NADAC, October 7, 2026); the strengths differ, so the two prices are not like for like. In FDA's classes, bisoprolol is a beta-adrenergic blocker and carvedilol an alpha-adrenergic blocker.
Check it at the source: the bisoprolol FDA label on DailyMed (effective March 11, 2026); the carvedilol FDA label on DailyMed (effective July 31, 2026).
Highlights of the bisoprolol record
Bisoprolol (Zebeta) · label of March 11, 2026
Used for
From the label: indicationsBisoprolol fumarate tablets are indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents.
On the market
- Earliest approval on file
- July 31, 1992
- Generic labelers
- 24 labelers
- Pharmacy cost
- $0.114 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 2
Highlights of the carvedilol record
Carvedilol (Coreg) · label of July 31, 2026
Used for
From the label: indicationsINDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure ( 1.1 ) left ventricular dysfunction following myocardial infarction in clinically stable patients ( 1.2 ) hypertension ( 1.3 ) 1.1 Heart Failure COREG is indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in […]
On the market
- Earliest approval on file
- September 14, 1995
- Generic labelers
- 41 labelers
- Pharmacy cost
- $0.0179 per tablet
Supply and safety
- Shortage
- No current entry
- Recalls
- 22
Source: FDA drug labels via openFDA (Bisoprolol label of March 11, 2026, Carvedilol label of July 31, 2026); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do bisoprolol and carvedilol differ on the record?
In FDA's classes, bisoprolol is a beta-adrenergic blocker and carvedilol an alpha-adrenergic blocker.
Half-life, in each label's words: Bisoprolol, “The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of …”; Carvedilol, “Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 …”
Generics: bisoprolol since 2000; carvedilol since 2007 (Drugs@FDA).
| Bisoprolol | Carvedilol | |
|---|---|---|
| Labeled for | High blood pressure | Heart failure, High blood pressure |
| Pharmacologic class | beta-Adrenergic Blocker | alpha-Adrenergic Blocker, beta-Adrenergic Blocker |
| How it works (label) | n/a | COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. |
| Half-life (label) | The plasma elimination half-life is 9 to 12 hours and is slightly longer in elderly patients, in part because of decreased renal function in that population. | Following oral administration, the apparent mean terminal elimination half-life of carvedilol generally ranges from 7 to 10 hours. |
| Earliest approval on file (Drugs@FDA) | July 31, 1992 | September 14, 1995 |
| First generic approved | November 16, 2000 | September 5, 2007 |
| Generic labelers (NDC) | 24 labelers | 41 labelers |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $0.114 per tablet (Bisoprolol fumarate 5 mg tablet) | $0.0179 per tablet (Carvedilol 6.25 mg tablet) |
| 12-month price change | -39% | -4% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 2 | 22 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 135,060 | 137,029 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What next?
- Alternatives to bisoprolol
- every medicine labeled for the same conditions